Healthcare - Biotechnology - NASDAQ - US
$ 1.845
5.73 %
$ 47.1 M
Market Cap
-1.63
P/E
CASH FLOW STATEMENT
-18.9 M
OPERATING CASH FLOW
10.2 M
INVESTING CASH FLOW
12.6 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Gain Therapeutics, Inc.
| Net Income | -22.3 M |
| Depreciation & Amortization | 83.6 K |
| Capital Expenditures | -15.4 K |
| Stock-Based Compensation | 3.26 M |
| Change in Working Capital | 442 K |
| Others | 702 K |
| Free Cash Flow | -18.9 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (22.3) | (17.6) | (13.9) | (3.6) | (2.2) | (1.1) |
| Depreciation & Amortization | 83.6 K | 64.2 K | 15.5 K | 9.59 K | 2.57 K | 741 |
| Deferred Income Tax | 0 | 0 | 1.1 | 0 | 0 | 0 |
| Stock Based Compensation | 3.3 | 1.5 | 0.8 | 81.6 K | 0 | 0 |
| Other Operating Activities | (0.4) | (0.2) | 34.1 K | 8.71 K | 10.1 K | 41.1 K |
| Change in Working Capital | 0.4 | 1.5 | (0.4) | 0.2 | 0.3 | 0.3 |
| Cash From Operations | (18.9) | (14.7) | (12.4) | (3.2) | (1.9) | (0.7) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 15.4 K | (0.1) | 94.2 K | 20.8 K | 13.7 K | 7.99 K |
| Other Items | 10.2 | (14.7) | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 10.2 | (14.8) | 94.2 K | 20.8 K | 13.7 K | 7.99 K |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 89.1 K | 78.8 K | 22 K | 0.7 | 0 | 1.0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 12.7 | 0 | (0.8) | 9.7 | 1.8 | 0 |
| Cash From Financing Activities | 12.6 | 78.8 K | 41.8 | 10.5 | 1.8 | 1.0 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 4.5 | (29.6) | 29.4 | 7.2 | 97.2 K | 0.2 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (18.9) | (14.8) | (12.5) | (3.3) | (1.9) | (0.8) |